SCHEMBL7513741

SCHEMBL7513741

Cn1cc(C(N)=O)c(C(=O)NC2CCC2)n1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.63
TSHR P16473 1/20 0.63
SMN1; SMN2 Q16637 2/20 0.61
KDM4E B2RXH2 1/20 0.47
ALPL P05186 1/20 0.47
HPGD P15428 2/20 0.46
ALDH1A1 P00352 2/20 0.44
MEN1 O00255 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HTT P42858 1/20 0.44
KMT2A Q03164 1/20 0.44
PDE10A Q9Y233 3/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
RET P07949 3/20 0.41
IRAK4 Q9NWZ3 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15403035 0.97 LMNA (0.67) LMNATSHRSMN1; SMN2KDM4EALPL
SCHEMBL7517973 0.96 SMN1; SMN2 (0.67) LMNATSHRSMN1; SMN2KDM4EALPL
SCHEMBL7521251 0.94 LMNA (0.58) LMNATSHRSMN1; SMN2KDM4EALPL
SCHEMBL7513747 0.83 LMNA (0.66) LMNATSHRSMN1; SMN2KDM4EALPL
SCHEMBL4279828 0.80 LMNA (0.70) LMNATSHRSMN1; SMN2KDM4EALPL
SCHEMBL7517978 0.79 SMN1; SMN2 (0.71) LMNATSHRSMN1; SMN2KDM4EALPL
SCHEMBL17966539 0.78 LMNA (0.42) LMNATSHRSMN1; SMN2HPGDIRAK4
SCHEMBL7515585 0.77 GAA (0.44) LMNATSHRSMN1; SMN2HPGDIRAK4
SCHEMBL7521252 0.77 LMNA (0.61) LMNATSHRSMN1; SMN2KDM4EALPL
SCHEMBL15401987 0.75 TP53 (0.42) LMNATSHRSMN1; SMN2KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2580207-B1 NITROGEN CONTAINING HETEROARYL COMPOUNDS HOFFMANN LA ROCHE (CH) 2017-09-27 EP disclosed
US-8703768-B2 Nitrogen containing heteroaryl compounds HOFFMANN-LA ROCHE INC. (US) 2014-04-22 US disclosed
US-8623866-B2 2014-01-07 US disclosed
EP-2580207-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2013-04-17 EP disclosed
WO-2011154327-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 WO disclosed
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2011-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110306589-A1 NITROGEN CONTAINING HETEROARYL COMPOUNDS PDE10A, PDE3A, PDE2A LMNA 2125/4885TSHR 1037/4885SMN1; SMN2 1370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.